What is the recommended management of heart failure in a patient with multiple myeloma?

Management of Heart Failure in Multiple Myeloma

In patients with multiple myeloma who develop heart failure, immediately assess for cardiac amyloidosis (AL amyloidosis) through monoclonal protein screening (serum free light chains, serum and urine immunofixation electrophoresis) and cardiac imaging, as this represents a distinct disease entity requiring urgent plasma cell-directed chemotherapy in addition to standard heart failure management. 1

Critical Initial Assessment

The first priority is determining whether heart failure results from:

• AL (light-chain) cardiac amyloidosis - requires immediate hematology intervention
• Treatment-related cardiotoxicity from myeloma therapies
• Standard heart failure exacerbated by myeloma-related factors (anemia, renal dysfunction, hyperviscosity)

Diagnostic Workup for AL Amyloidosis

Obtain the following immediately 1:

• Serum free light chains (sFLC)
• Serum immunofixation electrophoresis (SIFE)
• Urine immunofixation electrophoresis (UIFE)
• Echocardiography looking for: concentric LV hypertrophy, sparkling myocardial texture, biatrial dilation, restrictive filling pattern 2
• Cardiac biomarkers: troponin and NT-proBNP (elevated levels indicate worse prognosis) 2
• Cardiac MRI if available: diffuse subendocardial late gadolinium enhancement is highly specific 2

Critical pitfall: Do NOT use SPEP/UPEP alone to exclude monoclonal protein - these have lower sensitivity than immunofixation and miss the low-level monoclonal proteins typical in AL amyloidosis (unlike myeloma) 1.

Management Algorithm

If AL Cardiac Amyloidosis is Confirmed:

Initiate plasma cell-directed chemotherapy immediately - this is the primary treatment 1:

First-line regimen (preferred): Daratumumab + Cyclophosphamide + Bortezomib + Dexamethasone (Dara-CyBorD) 1

• This has supplanted high-dose melphalan with stem cell transplant as first-line therapy
• No absolute contraindications based on ejection fraction or cardiac status - unlike other malignancies, all patients should receive treatment regardless of cardiac function 1
• Goal: eradicate pathological plasma cells and remove light chains from circulation to prevent further organ damage and allow amyloid deposit regression 1

Concurrent cardiac management 3, 1:

• Assess vital signs and clinical congestion at each encounter
• Adjust diuretics based on volume status
• Monitor for treatment-related cardiac decompensation: worsening heart failure, atrial arrhythmias, thromboembolism 1
• Mandatory collaboration between hematology and cardiology throughout treatment 1

If Treatment-Related Cardiotoxicity (No Amyloidosis):

Identify the offending agent 4, 5:

Proteasome inhibitors:

• Carfilzomib: highest risk (36% develop dyspnea, LVEF reduction, pulmonary hypertension) 1
• Bortezomib: 6.4% develop grade 3 heart failure, 23% have >10% LVEF decrease 1
• Ixazomib: 10% develop grade 3 heart failure 1

Immunomodulatory drugs:

• Lenalidomide: paradoxical BNP increase in 86%, kidney dysfunction in 66% 1
• Pomalidomide: BNP increase in 88.8%, kidney dysfunction in 26% 1

Management approach:

• Standard guideline-directed medical therapy for heart failure per 2022 AHA/ACC/HFSA guidelines 3
• Multidisciplinary decision regarding continuation vs. discontinuation of cardiotoxic agent, weighing: severity of cardiac complication, myeloma prognosis, expected benefits, availability of alternative effective therapies 6
• Consider switching to less cardiotoxic alternatives within the same drug class

Baseline Prevention Strategies

Before initiating myeloma therapy 6, 7:

• Baseline ECG and echocardiography for all patients
• Risk stratification for cardiovascular disease
• Thromboprophylaxis mandatory for patients receiving immunomodulatory drugs 6

During treatment 6, 5:

• Close surveillance of high-risk patients (elderly, pre-existing CV disease, renal impairment)
• Serial monitoring of cardiac biomarkers and imaging in high-risk patients
• Prompt investigation of any cardiovascular symptoms

Prognosis Considerations

AL cardiac amyloidosis with myeloma: extremely poor prognosis, especially in advanced cardiac stages (Mayo stage IIIB) 2. The case evidence shows death within 5 months despite treatment when diagnosed at advanced stage, emphasizing the critical importance of early detection 2.

Treatment-related cardiotoxicity: generally reversible if detected early and managed appropriately, though cardiovascular events affect up to 7.5% of myeloma patients and adversely impact survival 4, 6.